Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Cupid has been allocated approximately 23.4 million units of female condoms per year
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Kygevvi combines two pyrimidine nucleosides, doxecitine and doxribtimine, which act by integrating deoxycytidine and deoxythymidine into skeletal muscle mitochondrial DNA
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Subscribe To Our Newsletter & Stay Updated